Stockscreener 앱 받기
42.45
0.82%
-0.35
시장 영업 전:
42.69
0.24
+0.57%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
Alkermes Plc (ALKS) Stock Analysis: Strong Buy Ratings And Promising Growth Potential - DirectorsTalk Interviews
Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference - MSN
Alkermes to present new data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, highlighting breadth of sleep medicine research - MSN
Alkermes Public Limited Company Trade Ideas — XETR:8AK - TradingView
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech - The Motley Fool
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes (ALKS) Showcases Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
[144] Alkermes plc. SEC Filing - Stock Titan
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo Finance
Alkermes to Present Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkermes to present narcolepsy drug data at SLEEP 2026 By Investing.com - Investing.com Canada
Alkermes to present narcolepsy drug data at SLEEP 2026 - Investing.com
New narcolepsy and hypersomnia treatment data from Alkermes at SLEEP 2026 - Stock Titan
Alkermes PLC (ALKS) Shares Surge 3.5% -- What GF Score of 75 Tel - GuruFocus
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story? - simplywall.st
Understanding Momentum Shifts in (ALKS) - Stock Traders Daily
Alkermes (NASDAQ: ALKS) CMO sells 9,000 shares, exercises 5,000 options under 10b5-1 plan - Stock Titan
Craig Hopkinson sells three 9,000-share tranches at Alkermes (NASDAQ: ALKS) - Stock Titan
Alkermes plc (ALKS) Stock Analysis: Solid Growth Potential with 28.2% Revenue Surge and Analyst Consensus - DirectorsTalk Interviews
Alkermes Insider Sold Shares Worth $687,007, According to a Recent SEC Filing - marketscreener.com
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
ALKS Q1 2026 Earnings: Narrower Loss Surprises, Stock Jumps 5.6%Consensus Beat Rate - The Legal Advocate
Alkermes (ALKS) finance VP exercises options and sells 16,217 shares - Stock Titan
Alkermes Plc Hits New 52-Week High at $40.78, Up 65% - Markets Mojo
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences - MSN
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat - AD HOC NEWS
Alkermes stock hits 52-week high at 39.57 USD By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at 39.57 USD - Investing.com
Alkermes to showcase leadership in psychiatry and orexin biology with new data at the American Society of Clinical Psychopharmacology annual meeting - MSN
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting - Business Wire
Alkermes Plc (ALKS) Stock Analysis: Unlocking Potential With A 23.47% Upside - DirectorsTalk Interviews
Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants - Stock Titan
Alkermes (ALKS) director gets new RSUs, options and tax withholding - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
Alkermes (NASDAQ: ALKS) director reports RSU vesting, option grant and tax-share withholding - Stock Titan
[Form 4/A] Alkermes plc. Amended Insider Trading Activity - Stock Titan
Alkermes (ALKS) director receives equity awards and corrects vesting terms - Stock Titan
Alkermes (ALKS) director reports RSU vesting, tax withholding and new stock options - Stock Titan
Alkermes (NASDAQ: ALKS) director logs RSU exercise, new option and RSU grants - Stock Titan
Avoiding Lag: Real-Time Signals in (ALKS) Movement - Stock Traders Daily
Alkermes Shareholders Approve Amended Stock Incentive Plan - The Globe and Mail
LYBALVI data detail real-world relapse and ER visit outcomes - Stock Titan
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences - Yahoo Finance
Alkermes (ALKS) shareholders approve 2018 equity plan, directors and auditor - Stock Titan
7.00%
0.08%
자본화:
|
볼륨(24시간):